Market Research Logo

C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016

C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016’, provides in depth analysis on C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted pipeline therapeutics.

The report provides comprehensive information on the C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4)
  • The report reviews C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


According to Global Markets Direct's, recently published report 'C-X-C Chemokine Receptor Type 4 – Pipeline Review, H1 2016'; C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) pipeline Target constitutes close to 28 molecules. Out of which approximately 22 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, Global Markets Direct says; C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells.

The report 'C-X-C Chemokine Receptor Type 4 – Pipeline Review, H1 2016' outlays comprehensive information on the C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 9, 1, 8 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.

Introduction
Global Markets Direct Report Coverage
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) Overview
Therapeutics Development
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Stage of Development
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Therapy Area
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Indication
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Unknown Stage Products
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Companies
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Universities/Institutes
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Companies Involved in Therapeutics Development
AdAlta Pty Ltd.
Ambrx, Inc.
Anchor Therapeutics, Inc.
Biokine Therapeutics Ltd.
BioLineRx, Ltd.
Bristol-Myers Squibb Company
Eli Lilly and Company
Globavir Biosciences, Inc.
GlycoMimetics, Inc.
NeED Pharma s.r.l.
Pharis Biotec GmbH
Polyphor Ltd.
Sanofi
TaiGen Biotechnology Co., Ltd.
Upsher-Smith Laboratories, Inc.
X4 Pharmaceuticals, Inc.
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Drug Profiles
(filgrastim + plerixafor) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALB-408 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-3114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATI-2341 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
balixafortide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKT-170 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BL-8040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
burixafor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBV-4086 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMI-1359 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hz-515H7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2510924 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize CXCR4 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-4043 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plerixafor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-5551 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Inhibit CXCR4 for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTX-9908 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-122 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize CXCR4 for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Antagonize CXCR4 for Oncology and Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate CXCR4 for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Target CXCR4 and SDF-1 for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulocuplumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
USL-311 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-4P001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-4P002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Dormant Projects
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Discontinued Products
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Featured News & Press Releases
May 25, 2016: GlycoMimetics plans to file IND application for GMI-1359
May 19, 2016: BioLineRx BL-8040 to be Presented at Upcoming Scientific Conferences
May 16, 2016: Upsher-Smith Announces Start Of First In Human Clinical Trial In Oncology With Novel CXCR4 Antagonist USL311
May 09, 2016: X4 Pharmaceuticals Announces Initiation of Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma
Apr 19, 2016: BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016
Apr 19, 2016: X4 Pharmaceuticals Announces Data Presentation for Lead Candidate X4P-001 at AACR Annual Meeting
Mar 29, 2016: BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML
Mar 23, 2016: BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment
Mar 17, 2016: GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016
Dec 14, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment
Dec 14, 2015: X4 Pharmaceuticals Announces FDA Allowance of X4P-001 IND for Phase 1b/2a Study of in Refractory Clear Cell Renal Cell Carcinoma
Dec 14, 2015: X4 Pharmaceuticals Unveils Development Strategy for CXCR4 Inhibitor Pipeline in Cancer Supported by $37.5 million Series A Financing
Dec 07, 2015: GlycoMimetics Presents Preclinical Data at ASH Annual Meeting Showing GMI-1359 Enhances Efficacy of Chemotherapy in FLT-3 AML Model
Nov 23, 2015: BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions
Nov 09, 2015: GlycoMimetics To Present Poster on GMI-1359 at at 57th Annual ASH Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by AdAlta Pty Ltd., H1 2016
Pipeline by Ambrx, Inc., H1 2016
Pipeline by Anchor Therapeutics, Inc., H1 2016
Pipeline by Biokine Therapeutics Ltd., H1 2016
Pipeline by BioLineRx, Ltd., H1 2016
Pipeline by Bristol-Myers Squibb Company, H1 2016
Pipeline by Eli Lilly and Company, H1 2016
Pipeline by Globavir Biosciences, Inc., H1 2016
Pipeline by GlycoMimetics, Inc., H1 2016
Pipeline by NeED Pharma s.r.l., H1 2016
Pipeline by Pharis Biotec GmbH, H1 2016
Pipeline by Polyphor Ltd., H1 2016
Pipeline by Sanofi, H1 2016
Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016
Pipeline by Upsher-Smith Laboratories, Inc., H1 2016
Pipeline by X4 Pharmaceuticals, Inc., H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Dormant Projects (Contd..2), H1 2016
Dormant Projects (Contd..3), H1 2016
Dormant Projects (Contd..4), H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report